Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Sanara MedTech (SMTI) over the last 11 years, with Q3 2025 value amounting to $1.2 million.

  • Sanara MedTech's Share-based Compensation rose 2018.8% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 2603.2%. This contributed to the annual value of $4.4 million for FY2024, which is 2885.29% up from last year.
  • Sanara MedTech's Share-based Compensation amounted to $1.2 million in Q3 2025, which was up 2018.8% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's Share-based Compensation ranged from a high of $1.8 million in Q4 2021 and a low of $228786.0 during Q3 2021
  • In the last 5 years, Sanara MedTech's Share-based Compensation had a median value of $857526.0 in 2023 and averaged $906478.1.
  • As far as peak fluctuations go, Sanara MedTech's Share-based Compensation surged by 24261.53% in 2021, and later tumbled by 5975.62% in 2022.
  • Over the past 5 years, Sanara MedTech's Share-based Compensation (Quarter) stood at $1.8 million in 2021, then tumbled by 59.76% to $731096.0 in 2022, then rose by 17.71% to $860559.0 in 2023, then soared by 38.94% to $1.2 million in 2024, then rose by 3.07% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.4 million for Q2 2025, and $1.3 million during Q1 2025.